Astrazeneca (AZN) Liabilities and Shareholders Equity (2009 - 2026)

Astrazeneca (AZN) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $114.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 7.31% year-over-year to $114.0 billion; the TTM figure through Mar 2026 stood at $455.0 billion (up 8.44% YoY), while the FY2025 annual figure was $114.1 billion, up 9.65% from the prior year.
• Liabilities and Shareholders Equity came in at $114.0 billion for Q1 2026 at Astrazeneca, roughly flat from $114.1 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $114.5 billion in Q3 2025, with the low at $313.0 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 5 years is $97.3 billion, with a median of $102.3 billion recorded in 2024.
• Across the five-year window, Liabilities and Shareholders Equity surged 92672.12% in 2022 and tumbled 99.68% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $96.5 billion in 2022, then sank by 99.68% to $313.0 million in 2023, then soared by 33138.02% to $104.0 billion in 2024, then grew by 9.65% to $114.1 billion in 2025, then slipped by 0.05% to $114.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $114.0 billion, $114.1 billion, and $114.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.